Who are Cambridge Epigenetix's investors?

Cambridge Epigenetix's investors include Third Point Ventures, Ahren, Ahren Innovation Capital, GV (Google Ventures), New Science Ventures, Sequoia Capital.

How much funding has Cambridge Epigenetix raised?

Cambridge Epigenetix has disclosed $12.3M raised across 1 round.

Where is Cambridge Epigenetix headquartered?

Cambridge Epigenetix is headquartered in Cambridge.

Cambridge Epigenetix

Cambridge · United Kingdom corporation · 6 known investors

cambridge-epigenetix.com ↗

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

BiotechDeep TechHealthtech

Founders & leadership

Jason MelladExecutive

Martin MurphyNamed on SEC filing

Bobby Yerramilli-RaoNamed on SEC filing

Somasundaram SubramaniamNamed on SEC filing

Timothy RinkNamed on SEC filing

Thomas HulmeNamed on SEC filing

Board

Alice Newcombe-Ellis inBoard directorFounding and General Partner at Ahren Innovation Capital

Shankar BalasubramanianBoard director

Investors · 6

Third Point VenturesMenlo Park

AhrenreportedCambridge

Ahren Innovation CapitalreportedCambridge, Cambridgeshirevia Alice Newcombe-Ellis · board

GV (Google Ventures)reportedMountain View · $250K – $50M

New Science VenturesreportedGreenwich · $2M – $8M

Sequoia CapitalreportedMenlo Park · $4.4M – $214M

Reported raises · per SEC filings

Form D private placements

$12.3M disclosed across 1 round · 2018

▶$12.3MraisedMay 2018 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Martin MurphyDirector
Jason MelladExecutive Officer, Director
Bobby Yerramilli-RaoDirector
Alice Newcombe-EllisDirector
Somasundaram SubramaniamDirector
Timothy RinkDirector
Thomas HulmeDirector
Shankar BalasubramanianDirector

Offering amount: $12.3M
Amount sold: $12.3M
First sale: Apr 2018
Incorporated: Corporation, United Kingdom
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cambridge Epigenetix Raises $88M in Series D Funding Round | GenomeWebgenomeweb.com · Nov 2021

Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platformglobenewswire.com · Nov 2021

Ahren Leads $30mn Funding Round in Cambridge Epigenetix - Ahren Innovationahreninnovationcapital.com · Apr 2018

Google backs Cambridge epigenetics spinoff in a $21M round | Fierce Biotechfiercebiotech.com · Mar 2016

Cambridge Epigenetix announces $21M financing round led by Google – Cambridge Enterpriseenterprise.cam.ac.uk · Mar 2016

Cambridge Epigenetix raises $5.5M – Cambridge Enterpriseenterprise.cam.ac.uk · Oct 2014

Frequently asked questions

What does Cambridge Epigenetix do?: The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.
Who are Cambridge Epigenetix's investors?: Cambridge Epigenetix's investors include Third Point Ventures, Ahren, Ahren Innovation Capital, GV (Google Ventures), New Science Ventures, Sequoia Capital.
How much funding has Cambridge Epigenetix raised?: Cambridge Epigenetix has disclosed $12.3M raised across 1 round.
Where is Cambridge Epigenetix headquartered?: Cambridge Epigenetix is headquartered in Cambridge.